Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Ralph Woessner"'
Autor:
Felix Huth, Hilmar Schiller, Yi Jin, Birk Poller, Carole Schuhler, Wendy Weis, Ralph Woessner, Anton Drollmann, Peter End
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 1, Pp 118-129 (2022)
Abstract Remibrutinib, a novel oral Bruton’s Tyrosine Kinase inhibitor (BTKi) is highly selective for BTK, potentially mitigating the side effects of other BTKis. Enzyme phenotyping identified CYP3A4 to be the predominant elimination pathway of rem
Externí odkaz:
https://doaj.org/article/671b42674e934937ade087fbd312624f
Autor:
Yan Ji, Claudio Calonder, Tiina Kirsilä, Alis Burciu, Matjaz Tisu, Yolandi Joubert, Nathalie Laurent, Eva Hua, Manmath Patekar, Anton Drollmann, Ralph Woessner
Publikováno v:
Pharmaceutics, Vol 15, Iss 9, p 2266 (2023)
Ligelizumab is a highly potent, humanized IgG1, anti-IgE monoclonal antibody. To explore its optimal subcutaneous delivery, the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of ligelizumab from two Phase 1 studies in healthy voluntee
Externí odkaz:
https://doaj.org/article/228589ca558e49258a69477a5e64236e
Autor:
Jordis Trischler, Ivan Bottoli, Reinhold Janocha, Christoph Heusser, Xavier Jaumont, Phil Lowe, Aurelie Gautier, Abhijit Pethe, Ralph Woessner, Hans‐Günter Zerwes, Stefan Zielen
Publikováno v:
Clinical & Translational Immunology, Vol 10, Iss 3, Pp n/a-n/a (2021)
Abstract Objective Ligelizumab is a humanised IgG1 anti‐IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than omalizumab on inhaled and skin allergen provocation responses in mild allergic asthma. T
Externí odkaz:
https://doaj.org/article/72f107318a284f9296f58eca83ccd8dc
Autor:
Dieter Seebach, Ralph Woessner, Hauke Hennecke, Henk Schulz, Hansjörg Schild, Alexander K. Nussbaum, Bruno Martinoni, Jürg V. Schreiber, Stefan Abele, Francis Bitsch
Publikováno v:
CHIMIA, Vol 52, Iss 12 (1998)
Interactions and cleavage reactions of ?-amino acids and ?-oligopeptides (up to nine residues, carrying the side chains of Ala, Val, Leu, Ile, Phe, Ser, Lys, and Hop) with biological systems, such as the most potent peptidases (pronase, proteinase K,
Externí odkaz:
https://doaj.org/article/5d36bb67889f4e9fa30370bea6c5fcc6
Autor:
Rowan, Stringer, Jin, Chen, Bharti, Shah, Jessie, Gu, Yiming, Zhang, William, Prince, Lloyd B, Klickstein, Ralph, Woessner
Publikováno v:
Clinical Pharmacology in Drug Development. 12:122-131
This open-label, randomized, 3-treatment, 3-period, 6-sequence, crossover study in healthy subjects compared the pharmacokinetic and pharmacodynamic properties of a lipid-based (soft gelatin capsule) prototype final market image (pFMI) formulation of
Autor:
Jin Chen, Rowan Stringer, Bharti Shah, Jessie Gu, Yiming Zhang, Melissa Hackling, William Prince, Ralph Woessner
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(11)
Tropifexor, a farnesoid X receptor agonist, is currently under clinical development for the treatment of nonalcoholic steatohepatitis. Tropifexor undergoes glucuronidation by uridine 5'-diphosphoglucuronosyltransferase (UGT) 1A1 and oxidation by cyto
Autor:
Hilmar Schiller, Felix Huth, Carole Schuhler, Anton Drollmann, Martin Kaul, Ralph Woessner, Bharti Shah, Wendy Weis, Peter End
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 172
Pharmacokinetic drug-drug interactions (DDIs) are investigated to ensure safety for patients receiving concomitant medications. Here, we present a strategy to characterise the DDI potential of remibrutinib, as an inhibitor of drug-metabolising enzyme
Autor:
Bharti Shah, Jin Chen, Rowan Stringer, William T Prince, Melissa Hackling, Leonel Reis da Silva Torrao, Prasanna Kumar Nidamarthy, Ralph Woessner, Jessie Gu
Publikováno v:
Journal of clinical pharmacologyReferences. 62(4)
Tropifexor, a non-bile acid farnesoid X receptor (FXR) agonist, has dose-proportional pharmacokinetics (PK) and no obvious major enterohepatic circulation. This open-label study investigated the effect of hepatic impairment (HI), as determined by Chi
Autor:
Felix Huth, Hilmar Schiller, Anton Drollmann, Wendy Weis, Ralph Woessner, Carole Schuhler, Birk Poller, Yi Jin, Peter End
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 15, Iss 1, Pp 118-129 (2022)
Clinical and Translational Science, Vol 15, Iss 1, Pp 118-129 (2022)
Remibrutinib, a novel oral Bruton’s Tyrosine Kinase inhibitor (BTKi) is highly selective for BTK, potentially mitigating the side effects of other BTKis. Enzyme phenotyping identified CYP3A4 to be the predominant elimination pathway of remibrutinib
Autor:
Ralph Woessner, Rachel Soon, Claudio Calonder, Julie Milojevic, Bruno Boutouyrie-Dumont, David M. Pariser, Irina Koroleva, Anke Hasselberg, Gerard Bruin
Publikováno v:
Clinical Pharmacology and Therapeutics
This open‐label disease‐drug–drug interaction study assessed whether blockade of the interleukin (IL)‐17A pathway by secukinumab and subsequent downregulation of inflammatory cytokines like IL‐6 or high‐sensitivity C‐reactive protein af